financetom
Business
financetom
/
Business
/
South Korea fines Credit Suisse for illegal stock short selling
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
South Korea fines Credit Suisse for illegal stock short selling
Jul 3, 2024 1:32 AM

SEOUL (Reuters) -South Korea's financial regulator imposed record high fines on two subsidiaries of the former Credit Suisse group for stock short-selling violations, the regulator said on Wednesday.

The Financial Services Commission (FSC) decided to impose fines of 16.9 billion won ($12.17 million) and 10.2 billion won on Credit Suisse AG, currently UBS AG, and Credit Suisse Singapore Ltd, respectively, it said in a statement.

Credit Suisse AG conducted naked short-selling trades worth 60.3 billion won from April 7, 2021 to June 9, 2022, and Credit Suisse Singapore Ltd. carried out such trades worth 35.3 billion won from Nov. 29, 2021 to June 9, 2022, the FSC said.

UBS, which took over Credit Suisse last year, did not immediately respond to a request for comment.

Naked short-selling of stocks, in which an investor sells shares without first borrowing them or determining they can be borrowed, is banned by the Capital Markets Act in South Korea.

Last month, South Korea decided to extend a market-wide ban on short-selling of stocks through the first quarter of 2025, to develop a system to control illicit trading practices.

($1 = 1,388.7600 won)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
X4 Pharmaceuticals' Xolremdi Approved by FDA For WHIM Syndrome
X4 Pharmaceuticals' Xolremdi Approved by FDA For WHIM Syndrome
Apr 29, 2024
11:19 AM EDT, 04/29/2024 (MT Newswires) -- X4 Pharmaceuticals ( XFOR ) said Monday that the US Food and Drug Administration has approved Xolremdi for use in patients 12 years and older with warts, hypogammaglobulinemia, infections and myelokathexis, or WHIM, syndrome to raise circulating mature neutrophils and lymphocytes. The approval was based on results of a late-stage trial that showed...
Update: Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump
Update: Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump
Apr 29, 2024
11:21 AM EDT, 04/29/2024 (MT Newswires) -- (Updates with Alcon's ( ALC ) reply in the fourth paragraph and current stock movement in the fifth paragraph.) Sight Sciences ( SGHT ) said Monday it has received a jury trial verdict of $34 million related to the patent-infringement case it filed in September 2021 against Alcon ( ALC ) in the...
Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children
Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children
Apr 29, 2024
11:19 AM EDT, 04/29/2024 (MT Newswires) -- Aquestive Therapeutics ( AQST ) said Monday that the US Food and Drug Administration has approved Libervant Buccal Film to treat intermittent, stereotypic episodes of frequent seizure activity, which are distinct from a patient's usual seizure pattern, in epileptic patients aged 2 years to 5 years old. Aquestive Chief Executive Officer Daniel Barber...
Update: Market Chatter: Boeing Initiates Dollar Bond Sale After Reporting Cash Burn
Update: Market Chatter: Boeing Initiates Dollar Bond Sale After Reporting Cash Burn
Apr 29, 2024
11:18 AM EDT, 04/29/2024 (MT Newswires) -- (Updates with additional information, response from Boeing ( BA ) and latest share price movement.) Boeing ( BA ) is working on a major bond sale, its first since reporting a Q1 loss and $3.9 billion of cash burn last week, Bloomberg News reported Monday, citing a person familiar with the matter. The...
Copyright 2023-2026 - www.financetom.com All Rights Reserved